Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 11Phase 1 9Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 4pembrolizumab 2Radiotherapy 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Ipilimumab 2Cyclophosphamide 2tislelizumab 1teprotumumab 1pazopanib 1lenvatinib 1gallium citrate 1fludarabine phosphate 1fludarabine 1evolocumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1cabozantinib 1auricularum 1aldesleukin 1Spectrum Analysis 1Specimen Handling 1Pemetrexed 1Oxymorphone 1Oxycodone 1Nivolumab 1Morphine 1Levorphanol 1Lapatinib 1Hydromorphone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasm Metastasis × aldesleukin × Clear all
NCT02774291 2023-08-04

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Albert Einstein College of Medicine

Phase EARLY_PHASE1 Terminated
3 enrolled 6 charts
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡